Precede Biosciences

Precede Bio is impacting precision medicine with a first-in-class liquid biopsy platform, redefining what can be learned from a simple🩸blood draw.

[Precede Biosciences @Precede_Bio]

We’re proud to share that Precede Biosciences has secured $83.5M in total financing to scale our next-generation precision diagnostics platform.

This capital supports continued growth amid strong commercial traction with leading biopharmaceutical developers advancing the next wave of precision medicines. More broadly, this milestone reflects growing conviction in the need for diagnostics built for target expression and pathway biology, the biomarkers most relevant to next-generation precision medicines, including antibody drug conjugates (ADCs), targeted protein degraders, and other next-generation precision medicines.

We’re grateful for the continued support of our existing investors, including Illumina Ventures, 5AM Ventures, Bristol Myers Squibb, Osage University Partners (OUP), Binney Street Capital, and Lilly Asia Ventures, and excited to welcome new strategic and institutional partners, including Labcorp Venture Fund, UPMC Enterprises, Mirae Asset Capital Life Science, Mirae Asset Capital, 28 Capital LLC, and Alexandria Venture Investments.

We’re also grateful for the commitment and belief of the team at SVB, who support the Precede Bio mission through strategic, non-dilutive financing.

Together, this group adds deep expertise to the Precede mission, a mission to meaningfully impact drug development success rates and ensure patients receive treatments fully aligned to the biology of their disease.

View press release: https://t.co/LDMKsHcQ8E

[Precede Biosciences @Precede_Bio]

@Precede_Bio is excited to share data at #ESMO24 demonstrating our unique platform’s capability to reveal tumor PSMA expression from a simple blood test that is highly correlated with PSMA-PET imaging.

View press release: https://t.co/3IYO2zB9XZ

#PrecisionMedicine #Healthcare #DrugDevelopment #ProstateCancer

[Precede Biosciences @Precede_Bio]

Check out the latest publication from @Precede_Bio's scientific co-founders and Scientific Advisory Board members, Drs. Matthew Freedman, @DrChoueiri and @SylvanBacaLab, published in Cell Reports highlighting the potential of comprehensive epigenomics to impact therapeutic decision-making in kidney cancer from a simple blood draw. View publication: https://t.co/u13DbBM15v

#DrugDevelopment #Healthcare #Oncology #Innovation

[Precede Biosciences @Precede_Bio]

@Precede_Bio is pleased to announce the newest member of our Scientific Advisory Board, Doron Lipson. Dr. Lipson is truly a visionary leader and we are grateful to benefit from his many decades of leadership in genomic application development to advance our comprehensive epigenomic liquid biopsy platform. #ScientificAdvisoryBoard

[Precede Biosciences @Precede_Bio]

Please join us in welcoming Josephine N. Harada to the @Precede_Bio leadership team. Josephine will be spearheading corporate and business development efforts for our novel comprehensive epigenomic #LiquidBiopsy platform. Welcome to the team, Josephine!

[Precede Biosciences @Precede_Bio]

Today is Boston's Pride celebration, a day in which our hometown celebrates the rich diversity and culture of the LGBTQ+ community. At @Precede_Bio, we strive to build a diverse and inclusive workplace that honors and values each of our team members. This Pride month, we celebrate and give a shout out to our LGBTQ+ team members, collaborators, friends, and family members.

[Precede Biosciences @Precede_Bio]

Watch @Precede_Bio's Jonathan Beagan summarize the data on our comprehensive epigenomic #LiquidBiopsy platform's ability to predict ER IHC status and quantify ER signaling pathway activity in breast cancer patients from 1 mL of plasma. View data: https://t.co/LC8T44TNRD #PrecisionMedicine #PrecisionOncology #Healthcare #DrugDevelopment

[Precede Biosciences @Precede_Bio]

@Precede_Bio is excited to share #ASCO24 scientific poster presentations demonstrating accurate HER2 status detection across multiple cancers and the ability to quantify ER pathway activation in breast cancer, all from a simple blood test. View press release: https://t.co/2G5grIqbLi #PrecisionMedicine #PrecisionOncology #Healthcare #DrugDevelopment

[Precede Biosciences @Precede_Bio]

Watch as Anthony D'Ippolito goes Behind the Science at #ASCO24 to describe how @Precede_Bio's comprehensive epigenomic #LiquidBiopsy platform can predict HER2 status and pathway activity across cancers from 1 mL of plasma. View data: https://t.co/9jduOhpYip #OncoAlert

[Precede Biosciences @Precede_Bio]

#ASCO24 starts today! Check out the latest data showing how @Precede_Bio's comprehensive epigenomic #LiquidBiopsy platform accurately predicted HER2 status for patients with breast, gastroesophageal, and ovarian cancers and ER-status and ER pathway activation for patients with advanced breast cancer. #PrecisionMedicine #PrecisionOncology #Healthcare #DrugDevelopment #OncoAlert

[Precede Biosciences @Precede_Bio]

#ASCO24 abstracts are now available. Check out @Precede_Bio's exciting new scientific presentations for our comprehensive epigenomic #LiquidBiopsy platform. View abstracts 3047 and 1066 at https://t.co/rZuy6D8qIR #PrecisionMedicine #PrecisionOncology #Healthcare #DrugDevelopment

[Precede Biosciences @Precede_Bio]

We are excited to announce that two abstracts for @Precede_Bio's comprehensive epigenomic liquid biopsy platform have been selected for presentation at #ASCO24, taking place from May 31-June 4, 2024 in Chicago. #PrecisionMedicine #PrecisionOncology #Healthcare #DrugDevelopment #ADCs

[Precede Biosciences @Precede_Bio]

https://t.co/8VuFYC3x60

[Precede Biosciences @Precede_Bio]

Today @Precede_Bio is excited to share three scientific poster presentations from #AACR24 for our unique, comprehensive epigenomic #LiquidBiopsy platform. #PrecisionMedicine #Healthcare #DrugDevelopment #ADCs

View press release: https://t.co/jyqJsixObK

[Precede Biosciences @Precede_Bio]

Juliann Chmielecki, PhD, summarizes key takeaways for @Precede_Bio's comprehensive epigenomic #LiquidBiopsy platform’s ability to reveal disease biology and therapeutic targets in #LungCancer. View data: https://t.co/mZKT6IiDAa

[Precede Biosciences @Precede_Bio]

@corrie_painter, PhD, summarizes key takeaways for the @precede_bio comprehensive epigenomic #LiquidBiopsy platform’s ability to reveal disease biology and therapeutic targets in #GastroesophagealCancer. View data: https://t.co/JBJkXM2nCX

[Precede Biosciences @Precede_Bio]

@corrie_painter, PhD, summarizes key takeaways for @Precede_Bio's comprehensive epigenomic #LiquidBiopsy platform’s ability to reveal disease biology and therapeutic targets in #GastroesophagealCancer. View data: https://t.co/JBJkXM2nCX

[Precede Biosciences @Precede_Bio]

It was a busy day for @Precede_Bio at our #AACR24 poster today. Great engagement and discussion. If you haven’t seen what we are up to, we have two more to go…come visit the team - @corrie_painter, Jonathan Beagan, Jamey Guess - on April 9 to see our data in GEA cancer and April 10 for our data in Lung cancer.

[Precede Biosciences @Precede_Bio]

Today, @Precede_Bio launched our #BehindtheScience video series at #AACR24. Watch Matthew Eaton, PhD, describe key takeaways for the proof-of-concept study for our comprehensive epigenomic #LiquidBiopsy platform. View data: https://t.co/JBJkXM2nCX

[Precede Biosciences @Precede_Bio]

#AACR24 starts today! Come meet the @Precede_Bio team - Carl Barrett, Jonathan Beagan, Jamey Guess, Corrie Painter, Rehan Verjee - during our upcoming presentations and learn how our comprehensive epigenomic #LiquidBiopsy platform informs on actionable drug targets, pathways, and mechanisms of resistance from 1mL of plasma. View presentation details: https://t.co/J9pxVVJxHy #PrecisionMedicine #PrecisionOncology #Healthcare #DrugDevelopment #ADCs